赞诺梅林在M4 mAChRR表现出同时存在的正性和性结合模式
Wessel A C Burger1,2, Vi Pham1, Ziva Vuckovic1
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Nature communications
|September 6, 2023
概括
治疗精神分裂症的药物萨诺梅林 (Xanomeline) 在两个位置结合M4肌肌酸乙胆受体 (M4 mAChR). 这种双重结合解释了其复杂的作用,并提供了新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
背景情况:
- M4肌肉酸乙胆受体 (M4 mAChR) 是治疗精神病,认知和成的关键标.
- 作为M4 mAChR激活剂的xanomeline在精神分裂症II期试验中显示出有前途,改善了PANSS分数.
研究的目的:
- 为了确定与人类M4 mAChR结合的xanomeline的活性状态冷-EM结构.
- 为了阐明在M4 mAChR.的xanomeline的结合机制.
主要方法:
- 活性状态冷电子显微镜 (冷电子显微镜) 用于确定结构.
- 分子动态模拟以支持结构发现.
- 药理学验证以确认配体活性.
主要成果:
- 冷EM结构揭示了两个与M4 mAChR结合的xanomeline分子.
- 一个xanomeline分子占据了orthosteric乙胆结合部位.
- 第二个xanomeline分子被发现在细胞外前庭性全位.
结论:
- 克萨诺梅林作为人类M4 mAChR.的双双奥托斯特和斯特连接体.
- 这种双重结合机制为克萨诺梅林复杂的药理学提供了洞察力.
- 这些发现突出了治疗开发的多种联体-GPCR相互作用模式.
更多相关视频
相关概念视频
Cholinergic Receptors: Muscarinic
2.4K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.4K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.3K
Cholinergic Antagonists: Pharmacokinetics
515
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
515
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.9K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.9K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.1K
Cholinergic Receptors: Nicotinic
2.9K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.9K


